JP2010519260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519260A5 JP2010519260A5 JP2009550652A JP2009550652A JP2010519260A5 JP 2010519260 A5 JP2010519260 A5 JP 2010519260A5 JP 2009550652 A JP2009550652 A JP 2009550652A JP 2009550652 A JP2009550652 A JP 2009550652A JP 2010519260 A5 JP2010519260 A5 JP 2010519260A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- pharmaceutical composition
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000969 carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 2
- 101150109738 Ptger4 gene Proteins 0.000 claims 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 2
- 229960002986 dinoprostone Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90349407P | 2007-02-26 | 2007-02-26 | |
| US60/903,494 | 2007-02-26 | ||
| PCT/CA2008/000351 WO2008104055A1 (en) | 2007-02-26 | 2008-02-22 | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519260A JP2010519260A (ja) | 2010-06-03 |
| JP2010519260A5 true JP2010519260A5 (enExample) | 2011-03-31 |
| JP5301469B2 JP5301469B2 (ja) | 2013-09-25 |
Family
ID=39720805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550652A Expired - Fee Related JP5301469B2 (ja) | 2007-02-26 | 2008-02-22 | Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8158671B2 (enExample) |
| EP (1) | EP2114877B1 (enExample) |
| JP (1) | JP5301469B2 (enExample) |
| CN (1) | CN101622230B (enExample) |
| AU (1) | AU2008221194B2 (enExample) |
| CA (1) | CA2679175C (enExample) |
| ES (1) | ES2400293T3 (enExample) |
| WO (1) | WO2008104055A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008136382A1 (ja) | 2007-04-26 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 二環性化合物およびその医薬用途 |
| ES2518919T3 (es) * | 2008-05-14 | 2014-11-05 | Astellas Pharma Inc. | Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética |
| CN102149384B (zh) * | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | 作为ep4受体拮抗剂的杂环酰胺衍生物 |
| WO2010087425A1 (ja) | 2009-01-30 | 2010-08-05 | 国立大学法人京都大学 | 前立腺癌の進行抑制剤および進行抑制方法 |
| WO2010121382A1 (en) * | 2009-04-21 | 2010-10-28 | Merck Frosst Canada Ltd. | Process for making indole cyclopropyl amide derivatives |
| MX2012012966A (es) * | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| WO2012039972A1 (en) | 2010-09-21 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| PL2729445T3 (pl) | 2011-07-04 | 2016-04-29 | Rottapharm Biotech Srl | Cykliczne pochodne aminowe jako antagoniści receptora EP4 |
| EP2729141B1 (en) | 2011-07-04 | 2015-12-09 | Rottapharm Biotech S.r.l. | Cyclic amine derivatives as ep4 receptor agonists |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| WO2014143591A1 (en) | 2013-03-12 | 2014-09-18 | Allergan, Inc. | Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors |
| CN105431416B (zh) | 2013-06-12 | 2019-01-08 | 科研制药株式会社 | 4-炔基咪唑衍生物和含有其作为有效成分的药物 |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| CA3002144C (en) | 2015-10-16 | 2024-01-23 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| MX385428B (es) | 2016-07-07 | 2025-03-04 | Ono Pharmaceutical Co | Combinación que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario. |
| WO2018162562A1 (en) | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| WO2018195123A1 (en) * | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| US11066405B2 (en) * | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| WO2019166022A1 (en) * | 2018-03-02 | 2019-09-06 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic carboxylic acids and salts thereof |
| CN112313208B (zh) | 2018-04-17 | 2024-04-19 | 泰普斯特医疗公司 | 双环羧酰胺及其使用方法 |
| US11718582B2 (en) | 2018-07-12 | 2023-08-08 | Rottapharm Biotech S.R.L. | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist |
| KR102861190B1 (ko) | 2019-01-22 | 2025-09-17 | 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 | Pge2/ep4 신호 전달을 억제하기 위한 화합물, 이의 제조 방법, 및 이의 의약적 용도 |
| EP3722319A1 (en) | 2019-04-09 | 2020-10-14 | Rottapharm Biotech S.r.l. | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
| EP3827828A1 (en) | 2019-11-29 | 2021-06-02 | Rottapharm Biotech S.r.l. | (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification |
| WO2021115560A1 (en) | 2019-12-09 | 2021-06-17 | Rottapharm Biotech S.R.L. | New fyn and vegfr2 kinase inhibitors |
| EP3885339A1 (en) | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof |
| EP4200281A4 (en) | 2020-08-18 | 2024-09-25 | Hutchison Medipharma Limited | PYRIMIDINONE COMPOUNDS AND THEIR USES |
| JP7816164B2 (ja) | 2020-11-13 | 2026-02-18 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
| WO2022247881A1 (zh) * | 2021-05-28 | 2022-12-01 | 凯复(苏州)生物医药有限公司 | 治疗肿瘤的联合疗法 |
| WO2022257960A1 (zh) * | 2021-06-08 | 2022-12-15 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的双环化合物 |
| EP4393906A4 (en) * | 2021-08-27 | 2026-03-04 | Keythera Suzhou Bio Pharmaceuticals Co Ltd | Solid form of an indole compound, method of manufacture thereof and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030010589A (ko) | 2000-03-09 | 2003-02-05 | 오노 야꾸힝 고교 가부시키가이샤 | 인돌 유도체, 그 제조 방법 및 용도 |
| AU2000234451B2 (en) * | 2000-03-24 | 2005-09-29 | Asterand Uk Acquisition Limited | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| CA2415742A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| CA2536870C (en) * | 2003-09-03 | 2009-10-27 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| ATE533766T1 (de) * | 2005-05-19 | 2011-12-15 | Merck Canada Inc | Chinolinderivate als ep4-antagonisten |
| JP5244091B2 (ja) * | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体 |
| CA2654811A1 (en) * | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
-
2008
- 2008-02-22 CA CA2679175A patent/CA2679175C/en not_active Expired - Fee Related
- 2008-02-22 CN CN2008800061949A patent/CN101622230B/zh not_active Expired - Fee Related
- 2008-02-22 AU AU2008221194A patent/AU2008221194B2/en not_active Ceased
- 2008-02-22 JP JP2009550652A patent/JP5301469B2/ja not_active Expired - Fee Related
- 2008-02-22 ES ES08714673T patent/ES2400293T3/es active Active
- 2008-02-22 US US12/527,736 patent/US8158671B2/en active Active
- 2008-02-22 WO PCT/CA2008/000351 patent/WO2008104055A1/en not_active Ceased
- 2008-02-22 EP EP08714673A patent/EP2114877B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009530398A5 (enExample) | ||
| JP2017513836A5 (enExample) | ||
| RU2017117413A (ru) | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона | |
| JP2009536191A5 (enExample) | ||
| JP2007302689A5 (enExample) | ||
| JP2008543854A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2010502730A5 (enExample) | ||
| EP2620432A3 (en) | Diarylhydantoin compounds | |
| JP2010525056A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| JP2012520866A5 (enExample) | ||
| JP2013519632A5 (enExample) | ||
| JP2010265321A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| JP2011527332A5 (enExample) | ||
| JP2017529389A5 (enExample) | ||
| JP2011246469A5 (enExample) | ||
| JP2015509075A5 (enExample) | ||
| JP2012523395A5 (enExample) | ||
| JP2013525356A5 (enExample) | ||
| NZ596820A (en) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | |
| JP2011046708A5 (enExample) |